MA
ITCI

MUFG Americas’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

MUFG Americas’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed – – 888
2022
Q3 		$0 Buy
+7
New +$366 ﹤0.01% 942
2017
Q3 		– Sell
-975
Closed -$12K – 1233
2017
Q2 		$12K Buy
+975
New +$11.3K ﹤0.01% 825

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

MUFG Americas's ITCI Position: Q4 2022 in Review

MUFG Americas sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2022, closing a stake of 7 shares.

MUFG Americas first reported a position in ITCI in Q2 2017 and held it in 2 quarters. The position peaked at $12K in Q2 2017. 281 funds tracked by Wall St. Rank hold ITCI as of Q4 2022.

  • MUFG Americas reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2022 after selling out during the quarter.
  • MUFG Americas sold 7 Intra-Cellular Therapies Inc. shares in Q4 2022.
  • MUFG Americas first reported a position in Intra-Cellular Therapies Inc. in Q2 2017 and held it in 2 quarters.
  • MUFG Americas's Intra-Cellular Therapies Inc. position peaked at $12K in Q2 2017.
  • 281 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2022.

Based on MUFG Americas's 13F filing for Q4 2022.